Invited Commentary: Lower Urinary Tract Symptoms and Inflammation - Weighing the Evidence

被引:7
作者
Freedland, Stephen J. [1 ,2 ,3 ,4 ]
Aronson, William J. [5 ,6 ]
机构
[1] Durham VA Med Ctr, Dept Surg, Durham, NC USA
[2] Duke Prostate Ctr, Durham, NC USA
[3] Duke Univ, Med Ctr, Div Urol Surg, Dept Surg, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[5] Greater Los Angeles VA Hlth Syst, Dept Surg, Los Angeles, CA USA
[6] Univ Calif Los Angeles, Med Ctr, Dept Urol, Los Angeles, CA 90024 USA
关键词
inflammation; prostate; urinary tract physiological phenomena; MEN;
D O I
10.1093/aje/kwp084
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lower urinary tract symptoms (LUTS) are a common condition, particularly among older men. The etiology of these symptoms is often obscure and not always clearly related to prostatic enlargement or benign prostatic hyperplasia. St. Sauver et al. (Am J Epidemiol. 2009;169(11):1281-1290) hypothesized that systemic inflammation may be associated with LUTS and benign prostatic hyperplasia. Using a well-defined cohort, they found that, in general, inflammation was not related to LUTS or to benign prostatic hyperplasia progression. However, men with the highest amount of systemic inflammation, as measured by C-reactive protein levels, were at increased risk of a rapid change in irritative voiding symptoms and decreased urinary flow but not obstructive voiding symptoms or prostate size. To what degree systemic inflammation relates to inflammation within the urinary system and specifically the bladder and/or prostate is unclear. Furthermore, to what degree inflammation within the urinary system contributes to LUTS is unclear. Given that clinical trials of antiinflammatory drugs for LUTS have been largely unsuccessful, the role of inflammation as a contributor to LUTS remains an interesting hypothesis that requires further study.
引用
收藏
页码:1291 / 1293
页数:3
相关论文
共 7 条
[1]   Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) [J].
Di Silverio, F ;
Bosman, C ;
Salvatori, M ;
Albanesi, L ;
Pannunzi, LP ;
Ciccariello, M ;
Cardi, A ;
Salvatori, G ;
Sciarra, A .
EUROPEAN UROLOGY, 2005, 47 (01) :72-79
[2]   The Influence of Statin Medications on Prostate-specific Antigen Levels [J].
Hamilton, Robert J. ;
Goldberg, Kenneth C. ;
Platz, Elizabeth A. ;
Freedland, Stephen J. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (21) :1511-1518
[3]   Urologic Diseases in America project: Analytical methods and principal findings [J].
Litwin, MS ;
Saigal, CS ;
Yano, EM ;
Avila, C ;
Geschwind, SA ;
Hanley, JM ;
Joyce, GF ;
Madison, R ;
Pace, J ;
Polich, SM ;
Wang, MM .
JOURNAL OF UROLOGY, 2005, 173 (03) :933-937
[4]   Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement [J].
Mills, Ian W. ;
Crossland, Anna ;
Patel, Anup ;
Ramonas, Henrikas .
EUROPEAN UROLOGY, 2007, 52 (02) :503-509
[5]   The Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial [J].
Nickel, J. Curtis ;
Roehrborn, Claus G. ;
O'Leary, Michael P. ;
Bostwick, David G. ;
Somerville, Matthew C. ;
Rittmaster, Roger S. .
EUROPEAN UROLOGY, 2008, 54 (06) :1379-1384
[6]   Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the third national health and nutrition examination survey [J].
Rohrmann, S ;
Smit, E ;
Glovannucci, E ;
Platz, EA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 159 (04) :390-397
[7]   Associations Between C-Reactive Protein and Benign Prostatic Hyperplasia/Lower Urinary Tract Symptom Outcomes in a Population-based Cohort [J].
Sauver, Jennifer L. St. ;
Sarma, Aruna V. ;
Jacobson, Debra J. ;
McGree, Michaela E. ;
Lieber, Michael M. ;
Girman, Cynthia J. ;
Nehra, Ajay ;
Jacobsen, Steven J. .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2009, 169 (11) :1281-1290